Skip to main content

Catalyst Calendar

Fri, Aug 7, 2026

1 updates

8:00 AM

Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET

lanternpharma.com

Mon, Aug 3, 2026

1 updates

7:30 AM

Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine

lanternpharma.com

Tue, Jul 28, 2026

1 updates

7:45 AM

Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer

lanternpharma.com

Thu, Jul 23, 2026

1 updates

8:01 AM

Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers

lanternpharma.com

Wed, Jul 8, 2026

1 updates

7:30 AM

Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer

lanternpharma.com

Tue, Jun 2, 2026

1 updates

8:13 AM

Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer

Trial Results • Phase 2lanternpharma.com